The first oral drug formulated by AI has been advanced into clinical development. 

CRDMO Quotient Sciences has announced a Phase I study of the drug was initiated at the company’s UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA).  

The study will assess the safety and pharmacokinetics of an oral solid dose formulation in healthy volunteers. 

Quotient Sciences believes the drug is the first formulated by AI to be evaluated in the clinic. 

The CRDMO says its formulation development programme empowers pharmaceutical and biotech partners to make faster, more informed decisions earlier in the development process. 

“This programme marks a significant advancement in harnessing the power of advanced machine learning alongside deep scientific expertise to streamline drug development,” said Andy Lewis, Chief Scientific Officer at Quotient Sciences. 

“This approach, coupled with our Translational Pharmaceutics platform, enables our customers to make earlier, more informed decisions with greater confidence, ultimately increasing the likelihood of clinical success.”